Dupuytren Disease Market Forecasts to 2030 - Global Analysis By Disease Type, Treatment, Diagnosis, Route of Administration, Distribution Channel, End User and By Geography

According to Stratistics MRC, the Global Dupuytren Disease Market is accounted for $4.40 billion in 2023 and is expected to reach $6.86 billion by 2030 growing at a CAGR of 6.6% during the forecast period. Dupuytren's disease, also known as Dupuytren's contracture, is a medical condition that affects the hands and fingers. It is characterized by the thickening and tightening of the connective tissue beneath the skin in the palm of the hand. The primary feature of Dupuytren's disease is the development of nodules or lumps in the palm, which may progress to form cords of tissue that pull the affected fingers inward.

Market Dynamics:

Driver:

Increasing incidence

As the global population ages, particularly in regions with a higher prevalence of this condition, there is a natural rise in the number of individuals affected by Dupuytren's disease. Moreover, heightened awareness and improved diagnostic capabilities contribute to the more accurate and timely identification of Dupuytren's disease cases. Overall, the escalating incidence of Dupuytren's disease propels market growth by creating opportunities for improved patient care and the development of novel treatment modalities.

Restraint:

High cost of treatment

The cost of treatment serves as a notable restraint in the Dupuytren's disease market, impacting the demand. Surgical interventions, such as fasciectomy or fasciotomy, and certain pharmaceutical treatments involve substantial costs; include hospitalization, surgeon fees, and post-operative care. Moreover, the potential for recurrence in Dupuytren's disease necessitates additional treatments, amplifying the overall cost for patients over time.

Opportunity:

Technological innovations in treatment options

Technological innovations in treatment options are a significant driver in the Dupuytren disease market, accelerating the demand. The introduction of collagenase injections has revolutionized the treatment of Dupuytren disease. Collagenase is an enzyme that can break down the contracted tissue, enabling the straightening of the affected fingers. This non-surgical approach avoids the need for incisions or anaesthesia and provides patients with a less-invasive treatment option.

Threat:

Limited treatment options

Dupuytren disease exhibits significant heterogeneity among patients, with variations in disease severity, affected hand joints, and response to treatments. This variability makes it challenging to predict treatment outcomes and select the most appropriate intervention for each individual. Some patients may experience limited improvement or recurrence of contractures even after undergoing treatment, leading to the need for additional interventions or a combination of treatment approaches. Therefore, the limited treatment options in the dupuytren disease market pose a challenge to market growth.

COVID-19 Impact

The COVID-19 pandemic has significantly impacted the Dupuytren disease market, introducing challenges that have influenced both patient care and market dynamics. The healthcare system's prioritization of resources toward managing the pandemic has led to disruptions in routine medical services, delaying the diagnosis and treatment of Dupuytren disease. Additionally, supply chain disruptions and manufacturing challenges during the pandemic have affected the availability and distribution of Dupuytren-specific treatments.

The radiation therapy segment is expected to be the largest during the forecast period

The radiation therapy segment is estimated to hold the largest share. Radiation therapy involves the use of high-energy radiation to target and reduce abnormal tissue growth associated with Dupuytren's disease. This non-invasive treatment modality is particularly considered for individuals with advanced stages of the disease, characterized by contractures and nodules impacting hand function. It is especially beneficial in cases where multiple fingers are affected or when the disease recurs after surgery.

The parenteral segment is expected to have the highest CAGR during the forecast period

The parenteral segment is anticipated to have lucrative growth during the forecast period. In Dupuytren's disease the parenteral route of administration plays a pivotal role in delivering therapeutic interventions directly into the patient's system, bypassing the gastrointestinal tract. This direct approach ensures rapid absorption and distribution of the therapeutic agent, allowing for optimal efficacy in managing the disease's symptoms. Moreover, the parenteral route minimizes the risk of degradation or alteration of the drug in the gastrointestinal environment, enhancing its bioavailability.

Region with largest share:

North America commanded the largest market share during the extrapolated period. The region comprises advanced healthcare infrastructure, a well-established regulatory framework, and a high prevalence of Dupuytren's disease, particularly in the aging population. The region's healthcare landscape encourages the adoption of advanced surgical procedures, injectable treatments, and non-invasive options. Moreover, collaborations between research institutions, pharmaceutical companies, and healthcare providers contribute to the development of novel therapies in this region.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period. In this region, there is a notable shift toward embracing advanced medical technologies and therapies for Dupuytren's disease. Increased research initiatives, collaborations between regional and international healthcare entities, and evolving healthcare policies contribute to the development and adoption of innovative treatment options. The market's growth in this region is further propelled by economic development, improved healthcare affordability, and a heightened focus on patient-centric care.

Key players in the market:

Some of the key players in the Dupuytren Disease Market include Pfizer Inc, AstraZeneca, Endo International plc, LEO Pharma A/S, Spear Pharmaceuticals, Hikma Pharmaceuticals PLC, Bristol-Meyers Squibb Company, Fresenius Kabi AG, GSK plc, Actiza Pharmaceutical Private Limited, Nantong Jinghua Pharmaceutical Co., Ltd, Novartis AG, Bayer AG., Johnson & Johnson Services Ltd. and Aurobindo Pharma.

Key Developments:

In August 2023, Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces a new strategic partnership and exclusive licensing agreement with SK Biopharmaceuticals, a global biotech company focused on the development of treatments for central nervous system (CNS) disorders and oncology, for the Middle East and North Africa.

In January 2022, Pfizer Inc. and BioNTech SE announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles, a debilitating, disfiguring and painful disease that impacts about one in three people in the United States during their lifetime.

Disease Types Covered:

• Type I
• Type II
• Type III

Treatments Covered:

• Needle Aponeurotomy
• Surgery
• Enzyme Injection
• Radiation Therapy
• Steroid Shot
• Occupational Therapy
• Other Treatments

Diagnosis Covered:

• X-Ray
• Physical Examination
• Other Diagnosis

Route of Administrations Covered:

• Parenteral
• Oral
• Other Route of Administrations

Distribution Channels Covered:

• Online Pharmacy
• Retail Pharmacy
• Other Distribution Channels

End Users Covered:

• Clinics
• Hospitals
• Academic & Research Institutes

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances